Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Lyra Capital
Watertown, Massachusetts, United States
- Ownership
- Private
- Employees
- ~45
- Development stage
- Other
01
Overview
ENLIGHTEN 2 Phase 3 trial for LYR-210 ongoing targeting CRS without nasal polyps; results will determine NDA viability. LYR-210 delivers 6 months of mometasone furoate with promising symptom relief and convenience vs surgery or biologics. Commercialization depends on FDA approval and differentiation from competitors like Dupixent[2][9][1].
- Therapeutic areas
- Pulmonology
- Modalities
- Small moleculeDrug-device combinationBiologic (via drug-eluting implants with mometasone furoate)
- Industry
- Investors
02
Partnerships
None publicly disclosed *(Lyra previously had partnerships under Maria Palasis, but none in current listing)[4]*
Beyond the preview
Go deeper on Lyra Capital.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lyra Capital.